The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle.


The combined loss of muscle strength and constant fatigue are disabling symptoms for cancer patients undergoing chemotherapy. Doxorubicin, a standard chemotherapy drug used in the clinic, causes skeletal muscle dysfunction and premature fatigue along with an increase in reactive oxygen species (ROS). As mitochondria represent a primary source of oxidant… (More)
DOI: 10.1016/j.freeradbiomed.2013.08.191


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics